Shigella Diarrhoea Prophylaxis Global Market Report 2025

The shigella diarrhoea prophylaxis market size has grown strongly in recent years. It will grow from $1.95 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. This historical growth can be linked to the rising incidence of shigella infections worldwide, increased awareness regarding food and waterborne illnesses, frequent outbreaks in refugee camps and densely populated urban settings, escalating antibiotic resistance in shigella strains, and a growing number of cases in children under five years old.

The shigella diarrhoea prophylaxis market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The anticipated expansion is driven by the risk of recurrent infections requiring preventive actions, the rise in public health initiatives promoting hygiene, the global prioritization of diarrhoea prevention programs, broader implementation of community health education, and increasing public acceptance and awareness of vaccination. Key trends over the forecast period include progress in vaccine research and development, introduction of innovative oral vaccines targeting shigella, advancements in vaccine delivery methods, creation of broad-spectrum prophylactic treatments, and the availability of rapid diagnostic tools to better direct prophylactic interventions.

The growing awareness of hygiene and sanitation is anticipated to drive the expansion of the shigella diarrhoea prophylaxis market in the coming years. Hygiene and sanitation encompass actions and environmental conditions that promote health and limit disease transmission through cleanliness and proper waste management. This increase in hygiene awareness is fueled by a better understanding of health risks, with more individuals recognizing the critical role cleanliness plays in preventing infectious disease spread. Such awareness supports shigella diarrhoea prophylaxis by reducing person-to-person transmission, as people who practice proper handwashing and waste disposal significantly decrease the chances of spreading the bacteria within communities. For example, in March 2024, the World Health Organization reported that 57% of the global population, or 4.6 billion people, had access to safely managed sanitation services. Of these, 33%, or 2.7 billion people, used private sanitation facilities connected to sewers where wastewater was treated, while 21%, or 1.7 billion people, used toilets or latrines that safely disposed of waste on-site. Thus, the rising awareness of hygiene and sanitation will boost growth in the shigella diarrhoea prophylaxis market.

Leading companies in the shigella diarrhoea prophylaxis market are concentrating on developing advanced solutions like tetravalent bioconjugate shigellosis vaccines to improve immune responses. These tetravalent bioconjugate vaccines are designed to protect against four major Shigella serotypes by linking bacterial polysaccharides to a carrier protein, enhancing the immune response. For instance, in November 2024, Valneva SE, a biotech company based in France, and LimmaTech Biologics AG, a Switzerland-based clinical-stage biotech firm, announced that the first participant had been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2). This vaccine candidate is currently the most clinically advanced tetravalent bioconjugate vaccine targeting shigellosis globally. This represents a key milestone in efforts to develop a vaccine against Shigella, a leading cause of severe diarrheal disease in children. The S4V2 vaccine will be tested for safety and preliminary efficacy in approximately 120 healthy adults aged 18 to 50 who have not previously been exposed to Shigella at three U.S. locations.

In August 2024, Valneva SE, a specialty vaccine company based in France, partnered with LimmaTech to accelerate the development of the advanced tetravalent shigella vaccine candidate. This collaboration allows Valneva to advance a promising program that addresses a critical unmet medical need and highlights LimmaTech’s expertise in vaccine development and their capability to rapidly accelerate program progress. LimmaTech is a Switzerland-based company focused on developing the tetravalent shigella vaccine candidate.

Major players in the shigella diarrhoea prophylaxis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Viatris Inc., Chongqing Zhifei Biological Products Co. Ltd., Macleods Pharmaceuticals Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Vaxcyte Inc., Valneva SE, Sanaria Inc., Intravacc B.V., LimmaTech Biologics AG, Eveliqure Biotechnologies GmbH, Intralytix Inc., Immuron Limited, Biocidium Biopharmaceuticals Inc., Institut Pasteur, and Hetero Drugs Limited.

North America was the largest region in the shigella diarrhoea prophylaxis market in 2024. The regions covered in shigella diarrhoea prophylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the shigella diarrhoea prophylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Shigella diarrhoea prophylaxis refers to preventive strategies aimed at reducing the risk of infection caused by Shigella bacteria, which are responsible for acute diarrhoeal illness. This type of prophylaxis targets breaking the transmission cycle of the pathogen by enhancing sanitation, promoting personal hygiene, ensuring safe food and water handling, and implementing public health interventions.

The primary forms of shigella diarrhoea prophylaxis include vaccination, antibiotic prophylaxis, public health initiatives, and hygiene education. Vaccination involves administering a vaccine to activate the immune system against specific pathogens. Vaccines can be given orally, parenterally, or via other routes and are utilized by various end-users including healthcare facilities, travel clinics, pharmacies, and government health programs.

The shigella diarrhoea prophylaxis market research report is one of a series of new reports that provides shigella diarrhoea prophylaxis market statistics, including the shigella diarrhoea prophylaxis industry global market size, regional shares, competitors with the shigella diarrhoea prophylaxis market share, detailed shigella diarrhoea prophylaxis market segments, market trends, and opportunities, and any further data you may need to thrive in the shigella diarrhoea prophylaxis industry. This shigella diarrhoea prophylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The shigella diarrhoea prophylaxis market consists of revenues earned by entities by providing services such as water quality testing, educational campaigns, infection control consulting, and food safety services. The market value includes the value of related goods sold by the service provider or included within the service offering. The shigella diarrhoea prophylaxis market also includes sales of hand sanitizers, antibacterial soaps, disinfectants, and surface cleaner. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.